Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Lieberman

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Journal of Psychiatry & Neuroscience : JPN|June 24, 2010
Brain volumes in psychotic youth with schizophrenia and mood disordersMohamed El-Sayed, R Grant Steen, Michele D Poe, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trialRobert Rosenheck, Marvin Swartz, Joseph McEvoy, et al.
Biological Psychiatry|June 26, 2007
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophreniaDaniel B Campbell, Philip J Ebert, Tara Skelly, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|July 28, 2012
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistanceAlkomiet Hasan, Peter Falkai, Thomas Wobrock, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|December 11, 2012
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effectsAlkomiet Hasan, Peter Falkai, Thomas Wobrock, et al.
Frontiers in Genetics|November 1, 2011
Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study)Hemant K Tiwari, Amit Patki, Jeffrey Lieberman, et al.
The American Journal of Psychiatry|March 4, 2006
Barriers to employment for people with schizophreniaRobert Rosenheck, Douglas Leslie, Richard Keefe, et al.
Neurobiology of Aging|October 6, 2012
C9ORF72 repeat expansions not detected in a group of patients with schizophreniaEdward D Huey, Peter L Nagy, Laura Rodriguez-Murillo, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 2, 2005
Measuring outcome priorities and preferences in people with schizophreniaRobert Rosenheck, Scott Stroup, Richard S E Keefe, et al.
Biological Psychiatry|May 15, 2002
Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjectsHandan Gunduz, Huwei Wu, Manzar Ashtari, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Journal of Psychiatry & Neuroscience : JPN|June 24, 2010
Brain volumes in psychotic youth with schizophrenia and mood disordersMohamed El-Sayed, R Grant Steen, Michele D Poe, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trialRobert Rosenheck, Marvin Swartz, Joseph McEvoy, et al.
Biological Psychiatry|June 26, 2007
Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophreniaDaniel B Campbell, Philip J Ebert, Tara Skelly, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|July 28, 2012
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistanceAlkomiet Hasan, Peter Falkai, Thomas Wobrock, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry|December 11, 2012
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effectsAlkomiet Hasan, Peter Falkai, Thomas Wobrock, et al.
Frontiers in Genetics|November 1, 2011
Association of Allelic Variation in Genes Mediating Aspects of Energy Homeostasis with Weight Gain during Administration of Antipsychotic Drugs (CATIE Study)Hemant K Tiwari, Amit Patki, Jeffrey Lieberman, et al.
The American Journal of Psychiatry|March 4, 2006
Barriers to employment for people with schizophreniaRobert Rosenheck, Douglas Leslie, Richard Keefe, et al.
Neurobiology of Aging|October 6, 2012
C9ORF72 repeat expansions not detected in a group of patients with schizophreniaEdward D Huey, Peter L Nagy, Laura Rodriguez-Murillo, et al.
The British Journal of Psychiatry : the Journal of Mental Science|December 2, 2005
Measuring outcome priorities and preferences in people with schizophreniaRobert Rosenheck, Scott Stroup, Richard S E Keefe, et al.
Biological Psychiatry|May 15, 2002
Basal ganglia volumes in first-episode schizophrenia and healthy comparison subjectsHandan Gunduz, Huwei Wu, Manzar Ashtari, et al.
Pageof 7